AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35345521 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression model and ANN model
Number of subjects: 155
Study 35345521 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IFN‐γ, MIG, and IP‐10 levels
Number of subjects: 155
Study 34101779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (20 IU Humulin R U‐100 b.i.d.) for 12 months
Number of subjects: 49
Study 34101779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily) for 12 months
Number of subjects: 49
Study 35524444 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide as an adjunctive treatment
Number of subjects: 0
Study 35524444 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32336695 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol 500 mg/day added to lipid-lowering therapy
Number of subjects: 876
Study 32336695 — intervention group
Group type: COMPARATOR
Intervention: Lipid-lowering agents (control group)
Number of subjects: 876
Study 33472992 — intervention group
Group type: EXPERIMENTAL
Intervention: VasoStat (VS)
Number of subjects: 40
Study 33472992 — intervention group
Group type: COMPARATOR
Intervention: TR Band (TR)
Number of subjects: 40
Study 32086915 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic injection of dexamethasone
Number of subjects: 242
Study 32086915 — intervention group
Group type: COMPARATOR
Intervention: Systemic administration group
Number of subjects: 242
Study 35677027 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality nursing services
Number of subjects: 72
Study 35677027 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing services
Number of subjects: 72
Study 33545387 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 168
Study 33545387 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampus avoidance PCI (HA‐PCI)
Number of subjects: 168
Study 33545387 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 168
Study 33545387 — intervention group
Group type: COMPARATOR
Intervention: Cumulative incidence of brain metastases at 2 years for PCI
Number of subjects: 168
Study 33545387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of brain metastases at 2 years for HA‐PCI
Number of subjects: 168
Study 33380482 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided relaxation-based virtual reality (VR-GR)
Number of subjects: 90
Study 33380482 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction-based virtual reality (VR-D)
Number of subjects: 90
Study 33380482 — intervention group
Group type: COMPARATOR
Intervention: 360 video (passive control)
Number of subjects: 90
Study 35224810 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioural therapy for insomnia (dCBT-I)
Number of subjects: 1721
Study 35224810 — intervention group
Group type: COMPARATOR
Intervention: Patient education
Number of subjects: 1721
Study 32046499 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation app (Headspace) for 3 months
Number of subjects: 250
Study 32046499 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation app (Headspace)
Number of subjects: 250
Study 32046499 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation app (Headspace) provided in semester 1
Number of subjects: 250
Study 32046499 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 250
Study 35749950 — intervention group
Group type: EXPERIMENTAL
Intervention: LED phototherapy (AsGaAl, λ850 ± 10 nm, 150 mW, 17 J/cm2, 57 s per session)
Number of subjects: 60
Study 35749950 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser phototherapy (AsGaAl, λ780 nm, 70 mW, 20.0 J/cm2, 240 s per session)
Number of subjects: 60
Study 35749950 — intervention group
Group type: COMPARATOR
Intervention: Non‐irradiated Control
Number of subjects: 60
Study 32529934 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapeutic keratectomy (PTK)
Number of subjects: 63
Study 32529934 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapeutic keratectomy (PTK) for macular dystrophy
Number of subjects: 63
Study 32529934 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapeutic keratectomy (PTK) for granular dystrophy
Number of subjects: 63
Study 36442441 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-Only
Number of subjects: 60
Study 36442441 — intervention group
Group type: EXPERIMENTAL
Intervention: PA+Cannabis
Number of subjects: 60
Study 36442441 — intervention group
Group type: COMPARATOR
Intervention: Attention-Control
Number of subjects: 60
Study 36442441 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 60
Study 33948969 — intervention group
Group type: EXPERIMENTAL
Intervention: RCC-A
Number of subjects: 51
Study 33948969 — intervention group
Group type: COMPARATOR
Intervention: RCC-B
Number of subjects: 51
Study 32605492 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care program based on Johnson's behavioral system model for 2 weeks
Number of subjects: 150
Study 32605492 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 35780089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 42
Study 35780089 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 42
Study 33608144 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/day
Number of subjects: 15
Study 32679045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical anesthesia
Number of subjects: 300
Study 32679045 — intervention group
Group type: COMPARATOR
Intervention: No intracervical anesthesia (Control)
Number of subjects: 300
Study 36260947 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature Infant Oral Motor Intervention (PIOMI) for 5 min/day for 14 days
Number of subjects: 60
Study 33298388 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary instruments
Number of subjects: 0
Study 33298388 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 0
Study 33298388 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 0
Study 35075765 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of amoxicillin
Number of subjects: 474
Study 35075765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study 33888404 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-axis, syringe-free in-plane approach (Group I, n = 30)
Number of subjects: 60
Study 33888404 — intervention group
Group type: COMPARATOR
Intervention: Short-axis out-of-plane approach (Group II, n = 30)
Number of subjects: 60
Study 32567984 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid 5% cream twice daily for 12 weeks
Number of subjects: 40
Study 32567984 — intervention group
Group type: COMPARATOR
Intervention: Topical tranexamic acid 5% cream plus intradermal injections of PRP every 3 weeks for 12 weeks
Number of subjects: 40
Study 35632459 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention message targeting kin care
Number of subjects: 969
Study 35632459 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention message targeting disease avoidance
Number of subjects: 969
Study 35632459 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 969
Study 33427016 — intervention group
Group type: COMPARATOR
Intervention: delta-9-tetrahydrocannabinol (THC)
Number of subjects: 128
Study 35221304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg/mL)
Number of subjects: 60
Study 35221304 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (0.01 mg/mL)
Number of subjects: 60
Study 34176611 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 264
Study 34176611 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes distress
Number of subjects: 264
Study 34176611 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-mediation path through automatic negative thinking and diabetes distress
Number of subjects: 264
Study 34125267 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotersen
Number of subjects: 165
Study 34125267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 35419636 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 124
Study 35419636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 33837162 — intervention group
Group type: EXPERIMENTAL
Intervention: IASTM
Number of subjects: 80
Study 33837162 — intervention group
Group type: EXPERIMENTAL
Intervention: Flossing
Number of subjects: 80
Study 33837162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IASTM and flossing
Number of subjects: 80
Study 33837162 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape
Number of subjects: 80
Study 33837162 — intervention group
Group type: COMPARATOR
Intervention: Control (nondominant shoulders)
Number of subjects: 80
Study 33814268 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa
Number of subjects: 44
Study 36026542 — intervention group
Group type: EXPERIMENTAL
Intervention: Taylor-Scham approach
Number of subjects: 15
Study 36026542 — intervention group
Group type: COMPARATOR
Intervention: FCU-Splitting approach
Number of subjects: 15
Study 36517170 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rhythm control
Number of subjects: 217
Study 36517170 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 217
Study 32920641 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 doses of 4.5 x 10^5 PfSPZ (Days 1, 3, 5, and 7; Week 16)
Number of subjects: 60
Study 32920641 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 9.0 × 10^5 PfSPZ (Group 2)
Number of subjects: 60
Study 32920641 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 18.0 × 10^5 PfSPZ (Group 3)
Number of subjects: 60
Study 32920641 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 27.0 × 10^5 for dose 1 and 9.0 × 10^5 for doses 2 and 3 (Group 4)
Number of subjects: 60
Study 32920641 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-boost (after 24 weeks)
Number of subjects: 60
Study 32920641 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 60
Study 32336211 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic workout using a lower extremity cycle ergometer and a balance protocol once a week
Number of subjects: 14
Study 32336211 — intervention group
Group type: COMPARATOR
Intervention: Balance protocol (Control Group)
Number of subjects: 14
Study 35395930 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational information intervention
Number of subjects: 26
Study 35395930 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal setting intervention
Number of subjects: 26
Study 36258845 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS-based optimized analgesia measures
Number of subjects: 120
Study 36258845 — intervention group
Group type: COMPARATOR
Intervention: Traditional analgesia measures
Number of subjects: 120
Study 32567654 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 68
Study 32567654 — intervention group
Group type: COMPARATOR
Intervention: Practice group
Number of subjects: 68
Study 32782111 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-acupressure applied to the TH-6 acupuncture point for 15 min twice a day for one week
Number of subjects: 120
Study 32782111 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 34406173 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked-color imaging (LCI)
Number of subjects: 205
Study 34406173 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-laser imaging (BLI)-bright
Number of subjects: 205
Study 34406173 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 205
Study 34406173 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (WLI, BLI-bright, LCI)
Number of subjects: 205
Study 32053977 — intervention group
Group type: EXPERIMENTAL
Intervention: Breezing™
Number of subjects: 28
Study 32053977 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 32053977 — intervention group
Group type: COMPARATOR
Intervention: Regular metabolism tracking
Number of subjects: 28
Study 33853109 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy (measured by electrodermal activity of auricular acupoints)
Number of subjects: 46
Study 33853109 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-assessment survey regarding interest in auriculotherapy
Number of subjects: 46
Study 33853109 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-assessment survey regarding willingness to travel for treatment
Number of subjects: 46
Study 33853109 — intervention group
Group type: COMPARATOR
Intervention: Comparison of median current and average ranking of AAs
Number of subjects: 46
Study 32072617 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4
Number of subjects: 141
Study 32072617 — intervention group
Group type: COMPARATOR
Intervention: 5% human albumin
Number of subjects: 141
Study 32569127 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-volume resistance training (HV-RT, 6 sets per exercise)
Number of subjects: 58
Study 32569127 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-volume resistance training (LV-RT, 3 sets per exercise)
Number of subjects: 58
Study 32569127 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-volume resistance training (HV-RT)
Number of subjects: 58
Study 32569127 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-volume resistance training (LV-RT)
Number of subjects: 58
Study 32569127 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT, no exercise)
Number of subjects: 58
Study 34507406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dual task
Number of subjects: 64
Study 34507406 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor dual task
Number of subjects: 64
Study 34507406 — intervention group
Group type: COMPARATOR
Intervention: Normal walking speed with obstacle
Number of subjects: 64
Study 35886043 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 4297
Study 33242251 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly staircase sprint interval exercise (stair snacks)
Number of subjects: 10
Study 33242251 — intervention group
Group type: COMPARATOR
Intervention: Sedentary condition
Number of subjects: 10
Study 32088934 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat social media platform as a patient reminder tool
Number of subjects: 222
Study 32088934 — intervention group
Group type: COMPARATOR
Intervention: Control group (no social media reminder)
Number of subjects: 222
Study 35325684 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta transcranial alternating current stimulation (tACS) at 5 Hz, 1 mA
Number of subjects: 18
Study 35325684 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 18
Study 35325684 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-anterior tACS
Number of subjects: 18
Study 34746425 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg thrice daily
Number of subjects: 75
Study 34746425 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 75
Study 34746425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 35322080 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR training
Number of subjects: 54
Study 35322080 — intervention group
Group type: COMPARATOR
Intervention: Conventional digit mobilization (CDM) training
Number of subjects: 54
Study 35322080 — intervention group
Group type: COMPARATOR
Intervention: Non-immersive VR training
Number of subjects: 54
Study 34673691 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone (Kerendia)
Number of subjects: 0
Study 32622397 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser transurethral vaporesection of the prostate (ThuVARP)
Number of subjects: 410
Study 32622397 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 410
Study 35642516 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ptES + active iBT (double-active)
Number of subjects: 210
Study 35642516 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ptES + sham iBT (ptES-only)
Number of subjects: 210
Study 35642516 — intervention group
Group type: COMPARATOR
Intervention: Sham ptES + sham iBT (double-sham)
Number of subjects: 210
Study 32576287 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (Paracetamol/Orphenadrine combination)
Number of subjects: 28
Study 32576287 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (Paracetamol/Orphenadrine combination)
Number of subjects: 28
Study 35184146 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% aqueous chlorhexidine gluconate (AQC)
Number of subjects: 199
Study 35184146 — intervention group
Group type: COMPARATOR
Intervention: 2% chlorhexidine gluconate in 70% isopropyl alcohol (ALC)
Number of subjects: 199
Study 34337834 — intervention group
Group type: EXPERIMENTAL
Intervention: Projected extinctions of invasive‐threatened species
Number of subjects: 0
Study 34337834 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive alien species (IAS) impact
Number of subjects: 0
Study 34337834 — intervention group
Group type: EXPERIMENTAL
Intervention: Species composition shift
Number of subjects: 0
Study 34337834 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological invasions
Number of subjects: 0
Study 32747473 — intervention group
Group type: COMPARATOR
Intervention: Distance learning program consisting of 3 program modules with online tutorials, webinars, booster video vignettes, and individualized antibiotic prescribing feedback reports over 11 months.
Number of subjects: 29762
Study 32747473 — intervention group
Group type: COMPARATOR
Intervention: Distance learning program
Number of subjects: 29762
Study 35770697 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluid‐based HIV self‐testing (HIVST)
Number of subjects: 32
Study 33542175 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxytocin (24IU)
Number of subjects: 218
Study 33542175 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 218
Study 33542175 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 218
Study 35509808 — intervention group
Group type: EXPERIMENTAL
Intervention: MyLifestyleCoach intervention
Number of subjects: 1142
Study 33545094 — intervention group
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac (Sputnik V) vaccine (0.5 mL/dose, prime-boost regimen with rAd26 and rAd5 vectors, administered intramuscularly with a 21-day interval)
Number of subjects: 21977
Study 33545094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21977
Study 33545094 — intervention group
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac (Sputnik V) vaccine
Number of subjects: 21977
Study 34197941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomization
Number of subjects: 40
Study 32459426 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback using digital step counters (pedometers)
Number of subjects: 215
Study 32459426 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 215
Study 35183238 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling-instructional-humor approach
Number of subjects: 24000
Study 35183238 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling-analogy approach
Number of subjects: 24000
Study 35183238 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling-emotion-focused approach
Number of subjects: 24000
Study 35183238 — intervention group
Group type: COMPARATOR
Intervention: No video (control group)
Number of subjects: 24000
Study 33639662 — intervention group
Group type: EXPERIMENTAL
Intervention: Takespro HPV intervention (health education through videos and booklets for 6 months)
Number of subjects: 128
Study 33639662 — intervention group
Group type: COMPARATOR
Intervention: Usual care from the school (control group)
Number of subjects: 128
Study 36443882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment (ISTp) using ultra-sensitive malaria rapid diagnostic test (us-RDT) and pyronaridine-artesunate (Pyramax®)
Number of subjects: 0
Study 36443882 — intervention group
Group type: COMPARATOR
Intervention: Standard intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine (SP)
Number of subjects: 0
Study 34100082 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential mixed-nutrient meals
Number of subjects: 1002
Study 32489146 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole (2.5 mg daily) and cyclophosphamide (50 mg daily) with Sorafenib (400 mg/bid daily)
Number of subjects: 90
Study 32489146 — intervention group
Group type: COMPARATOR
Intervention: letrozole (2.5 mg daily) and cyclophosphamide (50 mg daily) without Sorafenib
Number of subjects: 90
Study 32489146 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole and cyclophosphamide with/without Sorafenib
Number of subjects: 90
Study 32489146 — intervention group
Group type: EXPERIMENTAL
Intervention: High responders (based on Ki67 variation)
Number of subjects: 90
Study 37921933 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade flexible ureteroscopy (FURS)
Number of subjects: 61
Study 37921933 — intervention group
Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 61
Study 33495978 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management (SM)
Number of subjects: 48
Study 33495978 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 48
Study 33495978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition (NUT)
Number of subjects: 48
Study 33495978 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus Nutrition (EX+NUT)
Number of subjects: 48
Study 32727474 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of birth registration
Number of subjects: 383
Study 32727474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's education
Number of subjects: 383
Study 32727474 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban vs Rural residence
Number of subjects: 383